Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272 is registered in ClinicalTrials.gov with 23andMe, Inc. as lead sponsor.

NCT NCT05199272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies
Lead sponsor
23andMe, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 29, 2021
Completion date
March 31, 2025
Enrollment
141 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cancer with a high tumor mutational burden, clear cell renal cell carcinoma, epithelial ovarian cancer, extensive-stage small-cell lung cancer, fallopian tube cancer, msi-h cancer, neuroendocrine tumors, primary peritoneal carcinoma, solid tumor